Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Obstacles to the Adoption of Biosimilars for Chronic Diseases.

Literature DB >> 28459924

Obstacles to the Adoption of Biosimilars for Chronic Diseases.

Aaron Hakim¹, Joseph S Ross².

Abstract

Mesh：

Substances：

Year: 2017 PMID： 28459924 DOI： 10.1001/jama.2017.5202

Source DB: PubMed Journal: JAMA ISSN： 0098-7484 Impact factor: 56.272

Keyword Cloud
Cited

× No keyword cloud information.

14 in total

1. Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.

Authors: Brian Chen; Sumimasa Nagai; James O Armitage; Bartlett Witherspoon; Chadi Nabhan; Ashley C Godwin; Y Tony Yang; Anuhya Kommalapati; Sri Harsha Tella; Carlo DeAngelis; Dennis W Raisch; Oliver Sartor; William J Hrushesky; Paul S Ray; Paul R Yarnold; Bryan L Love; LeAnn B Norris; Kevin Knopf; Laura Bobolts; Joshua Riente; Stefano Luminari; Robert C Kane; Shamia Hoque; Charles L Bennett
Journal: Oncologist Date: 2019-03-06

2. Early Adoption of Biosimilar Growth Factors in Supportive Cancer Care.

Authors: Xiaoxue Chen; Abiy Agiro; John Barron; David Debono; Michael Fisch
Journal: JAMA Oncol Date: 2018-12-01 Impact factor: 31.777

3. Out-of-Pocket Costs for Infliximab and Its Biosimilar for Rheumatoid Arthritis Under Medicare Part D.

Authors: Jinoos Yazdany; R Adams Dudley; Grace A Lin; Randi Chen; Chien-Wen Tseng
Journal: JAMA Date: 2018-09-04 Impact factor: 56.272

4. Failure to Launch: Biosimilar Sales Continue to Fall Flat in the United States.

Authors: Jinoos Yazdany
Journal: Arthritis Rheumatol Date: 2020-04-23 Impact factor: 10.995

5. Infliximab biosimilar for treating neurosarcoidosis: tolerance and efficacy in a retrospective study including switch from the originator and initiation of treatment.

Authors: Quentin Riller; Camille Cotteret; Helga Junot; Neila Benameur; Julien Haroche; Alexis Mathian; Miguel Hie; Makoto Miyara; Patrick Tilleul; Zahir Amoura; Fleur Cohen Aubart
Journal: J Neurol Date: 2019-02-09 Impact factor: 4.849

Obstacles to the Adoption of Biosimilars for Chronic Diseases.

1. Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.

2. Early Adoption of Biosimilar Growth Factors in Supportive Cancer Care.

3. Out-of-Pocket Costs for Infliximab and Its Biosimilar for Rheumatoid Arthritis Under Medicare Part D.

4. Failure to Launch: Biosimilar Sales Continue to Fall Flat in the United States.

5. Infliximab biosimilar for treating neurosarcoidosis: tolerance and efficacy in a retrospective study including switch from the originator and initiation of treatment.

Review 6. Global Acceptance of Biosimilars: Importance of Regulatory Consistency, Education, and Trust.

7. Uptake of Biosimilars and Its Economic Implication for the Treatment of Patients with Rheumatoid Arthritis in Korea.

Review 8. The Breakthrough of Biosimilars: A Twist in the Narrative of Biological Therapy.

9. Assessment of Variation in State Regulation of Generic Drug and Interchangeable Biologic Substitutions.

10. Barriers to Oncology Biosimilars Uptake in the United States.